ROCKVILLE, Md., April 25,
2024 /PRNewswire/ -- AbelZeta Pharma, Inc.
("AbelZeta" or the "Company"), a global clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative and proprietary cell-based therapeutic products,
today announced the acceptance of an abstract related to the
clinical study of C-CAR031, an autologous, armored GPC3-targeting
chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular
carcinoma (HCC) for oral presentation at the American Society of
Clinical Oncology (ASCO) Annual Meeting, taking place
in Chicago May 31 to June 4, 2024. C-CAR031 is based
on a novel GPC3-targeting CAR-T designed by AstraZeneca
(LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta
receptor II (TGFβRII) dominant negative armoring discovery platform
and is manufactured by AbelZeta in China. C-CAR031 is being developed in
China under a co-development
agreement
between AbelZeta and AstraZeneca.1
Details of the oral presentation are as follows:
Abstract Title: "Phase I study of C-CAR031, a
GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with
advanced hepatocellular carcinoma (HCC)."
Abstract Number: 4019
Session Type and Title: Rapid Oral
Abstract – Gastrointestinal
Cancer – Gastroesophageal, Pancreatic, and
Hepatobiliary
Session Date and Time: 6/3/2024; 9:45 AM-11:15 AM CDT
About AbelZeta Pharma, Inc.
AbelZeta is a global
clinical-stage biopharmaceutical company with centers of excellence
in Rockville, Maryland and
Shanghai, China. AbelZeta is
focusing on developing innovative and proprietary cell-based
therapeutic products and is committed to ushering in bespoke
treatments that harness the body's own immune system to fight
against hematological malignancies and solid tumors, as well as
inflammatory and immunological diseases. AbelZeta advances research
and development in its own GMP facilities at its centers of
excellence for early-stage clinical studies, with a pipeline
comprised of CAR-T and TIL therapies.
Forward-Looking Statements
Statements in this
communication relating to plans, strategies, specific activities,
and other statements that are not descriptions of historical facts
are forward-looking statements. Forward-looking information is
inherently subject to risks and uncertainties, and actual
results could differ materially from those currently anticipated
due to a number of factors, which include any risks detailed from
time to time in the Company's reports. Such statements are based on
the management's current beliefs and expectations and are subject
to significant risks and uncertainties outside of management and
the Company's control. Given these uncertainties, you should not
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as otherwise required by
law, the Company does not undertake any obligation, and expressly
disclaims any obligation, to update, alter or otherwise revise any
forward-looking statements, whether written or oral, that may be
made from time to time, whether as a result of new information,
future events or otherwise.
Company Contact:
Sarah
Kelly
Director of Communications
AbelZeta Pharma, Inc.
+1 (240) 552 5870
sarah.kelly@abelzeta.com
www.abelzeta.com
References
1. AbelZeta. AbelZeta Pharma Announces Agreement with
AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T
Therapy in China. December 2023.
https://www.abelzeta.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting-302127271.html
SOURCE AbelZeta Pharma, Inc.